Skip to main content

Table 5 Effect of encapsulated IgY on performance and the incidence of diarrhea in pigs challenged with K88+ ETEC1

From: Chicken egg yolk antibodies (IgY) as non-antibiotic production enhancers for use in swine production: a review

Items No. of pigs Percentage of pigs with diarrhea after specific times (Fecal score in brackets2) Weight gain, g3 Recovery rate, (%)
9 h 24 h 48 h 72 h
Negative control, unchallenged 4 0 % (0.5) 0 % (0) 0 % (0.4) 0 % (0) +1400 ± 129a ——
Positive control 4 75 % (2.5) 75 % (2.5) 75 % (2.0) 75 % (2.0) −162.5 ± 25d 0 %
Non-encapsulated IgY 4 100 % (2.0) 75 % (1.3) 25 % (1.0) 0 % (0) +937.5 ± 111b 100 %
Microencapsulated IgY 4 75 % (2.0) 0 % (0) 0 % (0) 0 % (0) +1325 ± 119a 100 %
Aureomycin 4 100 % (2.0) 50 % (2.0) 75 % (1.5) 50 % (1.5) +650 ± 71c 50 %
  1. Li et al. [83]
  2. 1All pigs except negative control were orally challenged with 5 mL of viable E. coli K88 organisms (1011 cfu/mL per pig) at time 0 h. Challenged pigs were left untreated (positive control) or treated three times (−1, 4 and 9 h after bacterial challenge) on the first day and twice a day for two consecutive days each time with 0.4 g non-encapsulated IgY, 2 g of microencapsulated IgY (equivalent to 0.4 g of IgY) or 0.25 g of aureomycin. Diarrhea and weight gain were assessed for 3 days after challenge
  3. 2FC score is the mean fecal consistency score: 0, normal; 1, soft feces; 2, mild diarrhea; 3, severe diarrhea. Pigs with a fecal score of < 1 were considered not to have diarrhea
  4. 3Means in a column followed by same or no letter do not differ (P > 0.05)